Comparative Pharmacology
Head-to-head clinical analysis: TRIMPEX versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMPEX versus TRIMPEX 200.
TRIMPEX vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Antibiotic
Antibiotic